Updated 20:08 GMT, 15 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,886.30 +0.03% CL 88.56 -0.20% BTC 64,770.01 +1.00%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,886 +0.03% BTC $64,770 +1.00% VIX 19.30 +3.21% latest tape · as of 20:08 UTC · 15 Nov
The Screen · Healthcare · Medical Devices

Cerus Corp

CERS · NASDAQ · USD · Market cap $627M · 261 employees

Cerus Corporation operates as a biomedical products company.

FAIL · Does not pass the screen
1.99 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 20:08 UTC · 15 Nov · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price1.99 USD at the 13 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.51x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.33)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Distribution ?
Screened · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.33, read 2026-11-15
  • Ethical does not pass the values gate
Price1.99 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-11Read Markdown1.95+2.1% to today Accumulation gives way to Markdown after a 17% slide in 7 days
2026-11-04Read Accumulation2.34-15.0% to today Markdown gives way to Accumulation after a 9% slide in 5 weeks
2026-10-02Read Markdown2.56-22.3% to today ✓Distribution gives way to Markdown after an 18% slide in 6 weeks
2026-08-24Read Distribution3.13-36.4% to today ✓Accumulation gives way to Distribution after a 22% rise in 8 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Cerus Corp holds its Distribution at $1.99. Elevated stress, defensive posture warranted, held for 54 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateElevated stress, defensive posture warranted, held for 54 days
Price at the screen$1.99
ValuationN/A trailing · 0.00 forward price to earnings
Values screenFAIL · score 70.0
Beta1.77
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 43.70% Below 33% Interest-bearing debt is 43.7% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 28.36% Below 33% Cash held in interest-bearing accounts and securities is 28.4% of assets, under the one-third limit. Pass
Receivables 22.69% Below 49% Money owed to the company is 22.7% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Cerus's business is in a permissible area, but its interest-bearing debt is about 44% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when CERS's ethical verdict changes

Today CERS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.51x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
4.00Street low 5.00Street average 5.00Street high 1.99Price

Third-party analyst targets. The average target sits +151% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E0.0x
EPS, trailing-0.05
EPS, forward0.00
Revenue growth+24.1%strong top-line growth
Profit margin-4.4%currently unprofitable
Return on equity-15.4%not currently earning a positive return on equity
FCF yield0.36%
Debt to equity1.43a meaningful debt load worth watching
Current ratio1.63healthy short-term liquidity
Beta1.77much more volatile than the market
Short interest, float0.07%
52-week range1.15 - 3.47
MoatNONE
Market cap$627M
Employees261

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

CERS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-11 Markdown · changed $1.95 -16.7% Entry 11

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-11-04 Accumulation · changed $2.34 +3.5% Entry 10

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-10-28 Markdown $2.26 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-10-21 Markdown $2.26 -1.7% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-10-14 Markdown $2.30 -10.2% Entry 7

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-10-02 Markdown · changed $2.56 -18.2% Entry 6

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-08-24 Distribution · changed $3.13 +0.0% Entry 5

The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-07-24 Accumulation $3.13 +22.3% Entry 4

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 22.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-07-18 Accumulation $2.56 +0.0% Entry 3

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 80%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $5.

2026-07-03 Accumulation $2.56 +0.0% Entry 2

Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in CERS's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $2.52 +3.0% · $1,030 +3.0%
2 months $1.89 +37.3% · $1,373 +37.3%
3 months $1.70 +52.7% · $1,527 +52.7%
6 months $2.15 +20.7% · $1,207 +20.7%
1 year $1.44 +80.2% · $1,802 +80.2%
2 years $1.75 +48.3% · $1,483 +48.3%
3 years $2.52 +3.0% · $1,030 +3.0%
5 years $5.94 -56.3% · $437 -56.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CERS does next, these words stay.

Cerus Corp · CERS · Distribution · $1.99
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.